Erdafitinib,Vinflunine,Docetaxel,Pembrolizumab
Janssen,pierre fabre,Merck
['biomarker', ' uc,(-ucsd),(-ucsf),']
subset analysis of thor (erdaftinib vs chemo in fgfr+ve uc) showed benefit for upper tract disease, suggesting other biology beyond fgfr predict response. multiple methods have been used for fgfr expression. we ve not perfected this biomarker (as with pd-l1) #asco2023 
Interested in Urology Cancers, biomarkers and drug development.